Hong Kong Stocks Close Mixed; Ascletis Pharma Receives U.S. Nod to Begin Phase II Trial of ASC30

Published on 01/05/2026 at 03:45 am EST
(MT Newswires) -- Hong Kong stocks closed mixed Monday as investors parsed macro data from China and closely followed geopolitical developments in Latin America.
The Hang Seng Index rose marginally by around 8.77 points, or roughly 0.03%, to end at 26,347.24, while the Hang Seng China Enterprises Index inched lower by 20.52 points, or nearly 0.2%, to 9,148.47.
China's service sector continued to expand in December 2025, though growth softened to a six-month low, according to a private reading from RatingDog. The headline RatingDog China General Services Business Activity Index inched down to 52.0 points last month from 52.1 in November 2025, reflecting weaker new orders, particularly from abroad, as export business declined amid fewer tourists, according to the agency.
Investors also weighed the fallout from a turbulent weekend after the U.S. captured Venezuelan President Nicolas Maduro and President Donald Trump said Washington would place the country under temporary U.S. control, warning of further strikes if Caracas does not cooperate on oil and drug trafficking and raising the prospect of action involving Colombia and Mexico.
In corporate news, Ascletis Pharma (HKG:1672) has received U.S. regulatory approval to initiate the Phase II trial of its ASC30 oral medicine for the treatment of diabetes.
Shares of the firm closed 7% higher.
Tencent-backedInSilico Medicine entered into a multi-year research and development collaboration with Servier valued at up to $888 million, including up to $32 million in upfront and near-term research and development payments.
Shares of the firm were down nearly 1% at close.

Sumber : MT Newswires